Characterizing the Burden

Agricultural azole fungicides drive resistance to medical azole antifungals

Western Europe:
- 40% of antifungal-resistant *Aspergillus* infections in the UK linked to fungicides
- Up to 19% of *Aspergillus fumigatus* cases in Europe are antifungal-resistant (in some studies)

United States:
- Lack of surveillance
- Limited antifungal susceptibility testing
- Prevalence of resistant *Aspergillus fumigatus* unknown

50%-100% mortality rate for azole-resistant invasive aspergillosis

Use Medical Azoles Appropriately

Patient with invasive *Aspergillus* who is failing therapy

Obtain AFST
No lab capacity/testing at your institution? Contact CDC’s Antibiotic Resistance Lab Network (AR LAB Network)*

Be ready to transition to a broader therapeutic approach
- Avoid azole monotherapy
- Consider LAmB or voriconazole plus an echinocandin

*https://www.cdc.gov/drugresistance/ar-lab-networks/domestic.html

References

This educational initiative was funded in part by a cooperative agreement with the Centers for Disease Control and Prevention (CDC-RFA-CK20-2003) to the University of Alabama at Birmingham. The University of Alabama at Birmingham is collaborating with the Mycoses Study Group Education & Research Consortium and Terranova Medica, LLC, on this initiative. The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this resource center do not necessarily represent the policy of CDC or HHS and should not be considered an endorsement by the Federal Government.